Summary
Global Markets Direct’s, ‘Lupin Limited - Product Pipeline Review, 2016’, provides an overview of the Lupin Limited’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Lupin Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Lupin Limited
- The report provides overview of Lupin Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Lupin Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Lupin Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Lupin Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lupin Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupin Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Lupin Limited Snapshot 6
Lupin Limited Overview 6
Key Information 6
Key Facts 6
Lupin Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Lupin Limited - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Lupin Limited - Pipeline Products Glance 12
Lupin Limited - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Lupin Limited - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Lupin Limited - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Lupin Limited - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
Lupin Limited - Drug Profiles 18
Biosimilar for Oncology 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
etanercept biosimilar 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
LND-101001 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
LNP-1892 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule for Colon and Lung Cancer 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Biosimilar for Diabetes 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Biosimilar for Inflammation 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Biosimilar for Ophthalmology 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Biosimilar for Viral Infections 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule for Autoimmune Diseases 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Infectious Diseases 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule for Pain and Inflammation 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Biosimilar for Endocrinology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Lupin Limited - Pipeline Analysis 32
Lupin Limited - Pipeline Products by Target 32
Lupin Limited - Pipeline Products by Route of Administration 33
Lupin Limited - Pipeline Products by Molecule Type 34
Lupin Limited - Pipeline Products by Mechanism of Action 35
Lupin Limited - Recent Pipeline Updates 36
Lupin Limited - Dormant Projects 37
Lupin Limited - Company Statement 38
Lupin Limited - Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44
List of Tables
Lupin Limited, Key Information 6
Lupin Limited, Key Facts 6
Lupin Limited - Pipeline by Indication, 2016 9
Lupin Limited - Pipeline by Stage of Development, 2016 10
Lupin Limited - Monotherapy Products in Pipeline, 2016 11
Lupin Limited - Phase III, 2016 12
Lupin Limited - Phase II, 2016 13
Lupin Limited - Phase I, 2016 14
Lupin Limited - Preclinical, 2016 15
Lupin Limited - Discovery, 2016 16
Lupin Limited - Unknown, 2016 17
Lupin Limited - Pipeline by Target, 2016 32
Lupin Limited - Pipeline by Route of Administration, 2016 33
Lupin Limited - Pipeline by Molecule Type, 2016 34
Lupin Limited - Pipeline Products by Mechanism of Action, 2016 35
Lupin Limited - Recent Pipeline Updates, 2016 36
Lupin Limited - Dormant Developmental Projects,2016 37
Lupin Limited, Other Locations 39
Lupin Limited, Subsidiaries 40
List of Figures
Lupin Limited - Pipeline by Top 10 Indication, 2016 8
Lupin Limited - Pipeline by Stage of Development, 2016 10
Lupin Limited - Monotherapy Products in Pipeline, 2016 11
Lupin Limited - Pipeline by Target, 2016 32
Lupin Limited - Pipeline by Route of Administration, 2016 33
Lupin Limited - Pipeline by Molecule Type, 2016 34
Lupin Limited - Pipeline Products by Mechanism of Action, 2016 35
